Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · Real-Time Price · USD
2.190
+0.020 (0.92%)
At close: Apr 28, 2026, 4:00 PM EDT
2.223
+0.033 (1.50%)
After-hours: Apr 28, 2026, 7:53 PM EDT
Aethlon Medical Stock Forecast
AEMD's stock price has decreased by -92.82% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Aethlon Medical stock has a target of 15, which predicts an increase of 584.93% from the current stock price of 2.19.
Analyst Consensus: Hold
* Price targets were last updated on Aug 14, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Aethlon Medical is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $15 | Hold | Reiterates | $15 | +584.93% | Aug 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Initiates $15 | Hold | Initiates | $15 | +584.93% | Jul 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $560 | Strong Buy | Reiterates | $560 | +25,470.78% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $560 | Strong Buy | Reiterates | $560 | +25,470.78% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $560 | Strong Buy | Reiterates | $560 | +25,470.78% | Jan 30, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-9.85
from -85.77
EPS Next Year
-2.25
from -9.85
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -9.01 | -1.03 | ||||||
| Avg | -9.85 | -2.25 | ||||||
| Low | -10.52 | -3.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.